These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 33215029)

  • 21. An exosome-derived lncRNA signature identified by machine learning associated with prognosis and biomarkers for immunotherapy in ovarian cancer.
    Cui Y; Zhang W; Lu W; Feng Y; Wu X; Zhuo Z; Zhang D; Zhang Y
    Front Immunol; 2024; 15():1228235. PubMed ID: 38404588
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cuproptosis-related gene FDX1 as a prognostic biomarker for kidney renal clear cell carcinoma correlates with immune checkpoints and immune cell infiltration.
    Yao Y; Chen H; Lou M; Chen T
    Front Genet; 2023; 14():1071694. PubMed ID: 36755576
    [No Abstract]   [Full Text] [Related]  

  • 23. Identification of novel gene signature for lung adenocarcinoma by machine learning to predict immunotherapy and prognosis.
    Shu J; Jiang J; Zhao G
    Front Immunol; 2023; 14():1177847. PubMed ID: 37583701
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification and validation of key genes with prognostic value in non-small-cell lung cancer via integrated bioinformatics analysis.
    Wang L; Qu J; Liang Y; Zhao D; Rehman FU; Qin K; Zhang X
    Thorac Cancer; 2020 Apr; 11(4):851-866. PubMed ID: 32059076
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of molecular subtypes, risk signature, and immune landscape mediated by necroptosis-related genes in non-small cell lung cancer.
    Zhu J; Wang J; Wang T; Zhou H; Xu M; Zha J; Feng C; Shen Z; Jiang Y; Chen J
    Front Oncol; 2022; 12():955186. PubMed ID: 35965497
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comprehensive analyses of the heterogeneity and prognostic significance of tumor-infiltrating immune cells in non-small-cell lung cancer: Development and validation of an individualized prognostic model.
    Pang Z; Chen X; Wang Y; Wang Y; Yan T; Wan J; Du J
    Int Immunopharmacol; 2020 Sep; 86():106744. PubMed ID: 32623229
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Construction of a ferroptosis-related five-lncRNA signature for predicting prognosis and immune response in thyroid carcinoma.
    Qin Y; Zhang D; Zhang H; Hou L; Wang Z; Yang L; Zhang M; Zhao G; Yao Q; Ling R; Zhang J
    Cancer Cell Int; 2022 Sep; 22(1):296. PubMed ID: 36175889
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Construction of a redox-related gene signature for overall survival prediction and immune infiltration in non-small-cell lung cancer.
    Miao TW; Yang DQ; Gao LJ; Yin J; Zhu Q; Liu J; He YQ; Chen X
    Front Mol Biosci; 2022; 9():942402. PubMed ID: 36052170
    [No Abstract]   [Full Text] [Related]  

  • 29. Correlation of tumor mutational burden with prognosis and immune infiltration in lung adenocarcinoma.
    Li L; Li J
    Front Oncol; 2023; 13():1128785. PubMed ID: 36959799
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Novel Prognostic Risk Model for Cervical Cancer Based on Immune Checkpoint HLA-G-Driven Differentially Expressed Genes.
    Xu HH; Wang HL; Xing TJ; Wang XQ
    Front Immunol; 2022; 13():851622. PubMed ID: 35924232
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of TIMELESS and RORA as key clock molecules of non-small cell lung cancer and the comprehensive analysis.
    Xian H; Li Y; Zou B; Chen Y; Yin H; Li X; Pan Y
    BMC Cancer; 2022 Jan; 22(1):107. PubMed ID: 35078435
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Combined Detection of Immune Genes for Predicting the Prognosis of Patients With Non-Small Cell Lung Cancer.
    Tian WJ; Liu SS; Li BR
    Technol Cancer Res Treat; 2020; 19():1533033820977504. PubMed ID: 33256552
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The Expression of RTN1 in Lung Adenocarcinoma and 
Its Effect on Immune Microenvironment].
    Zhu S; Zu L; Xu S
    Zhongguo Fei Ai Za Zhi; 2022 Jun; 25(6):385-395. PubMed ID: 35747917
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comprehensive
    Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
    Front Immunol; 2022; 13():931906. PubMed ID: 35958598
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Construction of mRNA prognosis signature associated with differentially expressed genes in early stage of stomach adenocarcinomas based on TCGA and GEO datasets.
    Jiang F; Lin H; Yan H; Sun X; Yang J; Dong M
    Eur J Med Res; 2022 Oct; 27(1):205. PubMed ID: 36253873
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A mast cell-related prognostic model for non-small cell lung cancer.
    Yang Y; Qian W; Zhou J; Fan X
    J Thorac Dis; 2023 Apr; 15(4):1948-1957. PubMed ID: 37197495
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.
    Li B; Cui Y; Diehn M; Li R
    JAMA Oncol; 2017 Nov; 3(11):1529-1537. PubMed ID: 28687838
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Construction of an HLA Classifier for Early Diagnosis, Prognosis, and Recognition of Immunosuppression in Sepsis by Multiple Transcriptome Datasets.
    Chen Z; Chen R; Ou Y; Lu J; Jiang Q; Liu G; Wang L; Liu Y; Zhou Z; Yang B; Zuo L
    Front Physiol; 2022; 13():870657. PubMed ID: 35685286
    [No Abstract]   [Full Text] [Related]  

  • 39. A new immune signature for survival prediction and immune checkpoint molecules in non-small cell lung cancer.
    Han S; Jiang D; Zhang F; Li K; Jiao K; Hu J; Song H; Ma QY; Wang J
    Front Oncol; 2023; 13():1095313. PubMed ID: 36793597
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Construction of Prognostic Risk Model for Small Cell Lung Cancer Based on Immune-Related Genes.
    Deng F; Tao F; Xu Z; Zhou J; Gong X; Zhang R
    Comput Math Methods Med; 2022; 2022():7116080. PubMed ID: 36245844
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.